The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL HL Update 2021 | Novel approaches in HL
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, explores the next steps in the treatment and management of Hodgkin lymphoma, including the development of second-generation anti-PD-1 antibodies, CD30-targeting CAR T-cell therapies, as well as combination strategies investigated in relapsed/refractory HL patients. Dr Bröckelmann also touches on areas of unmet needs in HL, including the treatment of older HL patients, the importance of identifying response biomarkers as well as rational combination strategies. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
